SGMOHIGH SIGNALFINANCIAL10-K

SGMO faces imminent bankruptcy risk with stockholders' equity turning negative, cash depleted by 50%, and explicit warnings about potential liquidation "in the very near term."

The company has moved from a precarious financial position to an existential crisis, with stockholders' equity falling to negative $14.3M and management now explicitly warning of potential bankruptcy proceedings in the very near term. The dramatic increase in outstanding shares (from 224M to 414M) suggests recent dilutive equity raises that have failed to address the fundamental liquidity crisis.

Comparing 2026-03-30 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

Despite revenue growing 210% to $36.6M, SGMO's financial position deteriorated catastrophically with stockholders' equity turning negative, cash reserves cut in half to just $20.9M, and operating cash burn accelerating to $97.2M annually. The company's total assets declined 41% while losses deepened across all operational metrics, indicating that even significant revenue growth cannot offset the unsustainable cash burn rate. The massive share dilution combined with negative equity signals desperate fundraising attempts that have likely only delayed an inevitable liquidity crisis.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+209.6%
$11.8M→$36.6M

Strong top-line growth of 209.6% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-162.7%
$22.8M→-$14.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-61.8%
$267K→$102K

Capex reduced 61.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-50%
$41.9M→$20.9M

Cash declined 50% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-44.8%
-$67.1M→-$97.2M

Operating cash flow fell 44.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
-41.2%
$101.6M→$59.7M

Total assets contracted 41.2% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-30.7%
$51.7M→$35.8M

Current assets declined 30.7% — monitor working capital adequacy and short-term liquidity.

Accounts Receivable
Balance Sheet
-29.5%
$526K→$371K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
-25.5%
-$97.9M→-$122.9M

Net income declined 25.5% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-16.6%
-$104.0M→-$121.2M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-17
ADDED
As of March 25, 2026, a total of 414,274,017 shares of common stock, $0.01 par value per share were outstanding.
Forward-looking statements may include, but are not limited to, statements about: our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for substantial additional financing, and our ability to obtain the substantial additional financing that we need to support our operations and to continue to operate as a going concern, including the possibility that at any time we may elect or may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S.
Bankruptcy Code in the very near term; our expectations concerning the availability and adequacy of data and a clear regulatory pathway to support a potential Biologics License Application, or BLA, submission for isaralgagene civaparvovec and the anticipated timing and acceptance of such submission, and the potential for the BLA to be approved by the U.S.
These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
We will need substantial additional funding in the very near term to execute our operating plan and to continue to operate as a going concern.
+7 more — sign up free →
REMOVED
As of March 13, 2025, a total of 224,710,019 shares of common stock, $0.01 par value per share were outstanding.
These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties.
4 Table of Conte nts SUMMARY OF RISK FACTORS Our business involves significant risks.
We need substantial additional funding to execute our operating plan and to continue to operate as a going concern.
If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →